These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 15152132)

  • 1. Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial.
    Weintraub WS; Foster J; Culler SD; Becker ER; Parker K; Zhang Z; Kolm P; Douglas JS;
    J Invasive Cardiol; 2004 May; 16(5):257-9. PubMed ID: 15152132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial.
    Zhang Z; Foster JK; Kolm P; Jurkovitz CT; Parker KM; Murrah NV; Anderson GT; Douglas JS; Weintraub WS
    Am Heart J; 2006 Oct; 152(4):770-6. PubMed ID: 16996857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial.
    Douglas JS; Weintraub WS; Holmes D
    Clin Cardiol; 2003 Oct; 26(10):451-4. PubMed ID: 14579914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis.
    Morishita R
    Atheroscler Suppl; 2005 Dec; 6(4):41-6. PubMed ID: 16275167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary stent restenosis in patients treated with cilostazol.
    Douglas JS; Holmes DR; Kereiakes DJ; Grines CL; Block E; Ghazzal ZM; Morris DC; Liberman H; Parker K; Jurkovitz C; Murrah N; Foster J; Hyde P; Mancini GB; Weintraub WS;
    Circulation; 2005 Nov; 112(18):2826-32. PubMed ID: 16246948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
    Jang JS; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Kim DK; Seol SH; Kim DI; Cho KI; Kim BH; Park YH; Je HG; Jeong YH; Kim WJ; Lee JY; Lee SW
    Cardiology; 2012; 122(3):133-43. PubMed ID: 22832424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
    Inoue T; Uchida T; Sakuma M; Imoto Y; Ozeki Y; Ozaki Y; Hikichi Y; Node K
    J Am Coll Cardiol; 2004 Oct; 44(7):1408-14. PubMed ID: 15464320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
    Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
    Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis.
    Kwon SU; Cho YJ; Koo JS; Bae HJ; Lee YS; Hong KS; Lee JH; Kim JS
    Stroke; 2005 Apr; 36(4):782-6. PubMed ID: 15746463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cilostazol and clopidogrel after successful coronary stenting.
    Lee SW; Park SW; Hong MK; Lee CW; Kim YH; Park JH; Kang SJ; Han KH; Kim JJ; Park SJ
    Am J Cardiol; 2005 Apr; 95(7):859-62. PubMed ID: 15781016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent.
    Chen YD; Lu YL; Jin ZN; Yuan F; Lü SZ
    Chin Med J (Engl); 2006 Mar; 119(5):360-6. PubMed ID: 16542577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial.
    Cohen DJ; Murphy SA; Baim DS; Lavelle TA; Berezin RH; Cutlip DE; Ho KK; Kuntz RE;
    J Am Coll Cardiol; 2004 Nov; 44(9):1801-8. PubMed ID: 15519010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial.
    Lee YS; Bae HJ; Kang DW; Lee SH; Yu K; Park JM; Cho YJ; Hong KS; Kim DE; Kwon SU; Lee KB; Rha JH; Koo J; Han MG; Lee SJ; Lee JH; Jung SW; Lee BC; Kim JS
    Cerebrovasc Dis; 2011; 32(1):65-71. PubMed ID: 21613787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction.
    Inoue T; Kobayashi M; Uetsuka Y; Uchiyama S
    Circ J; 2006 Apr; 70(4):453-8. PubMed ID: 16565564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
    Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
    J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the randomized, multicenter EREMUS trial, a study that investigates how to achieve low restenosis and early reendothelialization after percutaneous coronary interventions.
    Cortese B; Danzi GB; Pitì A; Severi S; Limbruno U
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):32-7. PubMed ID: 21413116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The vascular effects of cilostazol.
    Weintraub WS
    Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):56B-60B. PubMed ID: 16498513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.